Pipeline Flex / Pipeline Vantage with Shield Technology
Medtronic Neurovascular (Irvine, CA)
(Medtronic) Vantage), CE, NMPA | Evidence Level: Level 1 The Pipeline Embolization Device has proven to be a safe and effective device for the treatment of intracranial aneurysms. The Pipeline Vantage Flow Diverter (PVFD) with Shield Technology is the new fourth generation of this implant, with modifications made compared to previous iterations.
(Medtronic) Vantage), CE, NMPA | Evidence Level: Level 1
Generation Evolution
The Pipeline Embolization Device has proven to be a safe and effective device for the treatment of intracranial aneurysms. The Pipeline Vantage Flow Diverter (PVFD) with Shield Technology is the new fourth generation of this implant, with modifications made compared to previous iterations. The four generations of the Pipeline system represent a continuous engineering evolution: Generation
Device
Key Advance
1st (2011)
Pipeline Embolization Device (PED)
FDA approval; PITA/PUFS data; established FD concept
2nd
Pipeline FLEX
Enhanced delivery; loadand-pull deployment; resheathable
3rd
Pipeline FLEX with Shield
Phosphorylcholine surface modification; reduced thrombogenicity
4th (2022+)
Pipeline Vantage
Improved deliverability; Shield Technology; 027 + 021 MC variants
Design and Engineering
The device is made of 48 braids: 36 cobalt-chromium and 12 platinum wires for radiopacity. Shield Technology is a surface modification where inert synthetic phosphorylcholine (PC) polymer is covalently-chemically-bonded to the strands that make up the Pipeline device implant. It is recommended to use a 0.027" microcatheter for the delivery of Pipeline Flex with Shield Technology flow diverters. The phosphorylcholine (PC) surface mimics the outer membrane of red blood cells, presenting a biologically inert surface that resists nonspecific protein adsorption and platelet adhesion. The Pipeline Vantage device should enhance the deliverability and lower material thrombogenicity associated with the established Pipeline Flex Embolization Device, based
upon analogous thrombotic reductions seen in peripheral stent applications using PC surface modification.
Sizing Matrix
- Diameter
- Length
- Notes
- 2.5–5.0 mm
- 10–35 mm
- Size to largest landingzone diameter
- Pipeline Vantage: Fourth Generation
- The Pipeline Vantage embolization device (Medtronic) is the fourth generation of Pipeline
- flow diverter devices, offering numerous technical improvements. The fourth-generation flow
- diverter was successfully deployed in all cases as planned, without the need for
- angioplasty.
- The Pipeline Vantage 027 flow diverter became available in the United States. Investigators
- report an observational study of its safety and early angiographic response in the treatment
- of internal carotid artery aneurysms. Twenty-four aneurysms (mean size 4.2 ± 2.7 mm) in
- 20 patients underwent Vantage 027 embolization; clinical follow-up at 6 months revealed no
- major/minor stroke and a single reversible ischemic attack following DAPT non-compliance.
- Multicenter Evidence: Pipeline Flex and Vantage (AJNR 2024)
- The multicenter results demonstrate high feasibility, procedural safety, and efficacy of the
- surface-modified Pipeline flow diverters.
- Vanguard Study: Pipeline Vantage 6-Month Results
- The technical success rate was 98%. The mean clinical follow-up time was 5.5 months. In
- patients presenting with unruptured aneurysms there were no deaths, 3 (6.4%) major
- complications and 7 (13%) minor complications.
- Posterior Circulation: Pipeline Vantage
- The efficacy and safety of the Pipeline Vantage in treating posterior circulation saccular
- aneurysms are not well investigated. At the latest imaging follow-up available (median 14.3
- months), complete aneurysm occlusion (Class I, Raymond-Roy occlusion classification)
- was achieved in 50% of cases, residual neck (Class II) in 41.7%, and residual aneurysm
- (Class III) in 8.3%. These posterior circulation occlusion rates are meaningfully lower than
- anterior circulation benchmarks, reinforcing the warning to reserve posterior/giant cases for
- high-volume operators.
- Key Landmark Trials: Pipeline Evidence Pyramid
- Trial
- Year
- n
- Key Finding
- PITA
- 2008
- Proof of concept;
- 93% occlusion at 6
- months
- PUFS
- 2013
- 73.6% complete
- occlusion;
- durability of
- large/giant ICA
- treatment
- IntrePED
- 2015
- Real-world safety;
- 8.4% neurologic
- morbidity/mortality
- SHIELD (surface)
- 2018
- Bench/clinical
- PC coating
- reduces
- thrombogenicity
- ADVANCE
- (Vantage)
- Ongoing
- RCT
- Fourth-generation
- RCT; NMPA/FDA
- registration
- Vanguard
- 2024
- 47+
- 98% technical
- success; 6-month
- results published
Deployment Sequence
Position 0.027" microcatheter distal to neck; unsheath distal end and anchor Deploy with push-and-torque (“load and pull”) ensuring wall apposition across the neck Massage with wire or balloon if mal-apposed; confirm with VasoCT or cone-beam CT For large sacs: jail a coiling microcatheter and add loose coils before final detachment ──────────────────────────────────────────────────
Curated external education for the Flow Diverters family. Media is provided for reference under fair-use/educational terms and credited to its source; it supplements the printed Atlas.
Procedural & preparation videos
Image references
- Pipeline Flex flow diverter product imagery
Credit: Medtronic · reference-only
- FRED flow diverter product imagery
Credit: Terumo Neuro (MicroVention) · reference-only
Chapter 4
Flow Diverters
See all devices and foundational principles in this family.
Overview
(Medtronic) Vantage), CE, NMPA | Evidence Level: Level 1
Generation Evolution
The Pipeline Embolization Device has proven to be a safe and effective device for the treatment of intracranial aneurysms. The Pipeline Vantage Flow Diverter (PVFD) with Shield Technology is the new fourth generation of this implant, with modifications made compared to previous iterations. The four generations of the Pipeline system represent a continuous engineering evolution: Generation
Device
Key Advance
1st (2011)
Pipeline Embolization Device (PED)
FDA approval; PITA/PUFS data; established FD concept
2nd
Pipeline FLEX
Enhanced delivery; loadand-pull deployment; resheathable
3rd
Pipeline FLEX with Shield
Phosphorylcholine surface modification; reduced thrombogenicity
4th (2022+)
Pipeline Vantage
Improved deliverability; Shield Technology; 027 + 021 MC variants
Design and Engineering
The device is made of 48 braids: 36 cobalt-chromium and 12 platinum wires for radiopacity. Shield Technology is a surface modification where inert synthetic phosphorylcholine (PC) polymer is covalently-chemically-bonded to the strands that make up the Pipeline device implant. It is recommended to use a 0.027" microcatheter for the delivery of Pipeline Flex with Shield Technology flow diverters. The phosphorylcholine (PC) surface mimics the outer membrane of red blood cells, presenting a biologically inert surface that resists nonspecific protein adsorption and platelet adhesion. The Pipeline Vantage device should enhance the deliverability and lower material thrombogenicity associated with the established Pipeline Flex Embolization Device, based
upon analogous thrombotic reductions seen in peripheral stent applications using PC surface modification.
Sizing
Sizing Matrix
- Diameter
- Length
- Notes
- 2.5–5.0 mm
- 10–35 mm
- Size to largest landingzone diameter
- Pipeline Vantage: Fourth Generation
- The Pipeline Vantage embolization device (Medtronic) is the fourth generation of Pipeline
- flow diverter devices, offering numerous technical improvements. The fourth-generation flow
- diverter was successfully deployed in all cases as planned, without the need for
- angioplasty.
- The Pipeline Vantage 027 flow diverter became available in the United States. Investigators
- report an observational study of its safety and early angiographic response in the treatment
- of internal carotid artery aneurysms. Twenty-four aneurysms (mean size 4.2 ± 2.7 mm) in
- 20 patients underwent Vantage 027 embolization; clinical follow-up at 6 months revealed no
- major/minor stroke and a single reversible ischemic attack following DAPT non-compliance.
- Multicenter Evidence: Pipeline Flex and Vantage (AJNR 2024)
- The multicenter results demonstrate high feasibility, procedural safety, and efficacy of the
- surface-modified Pipeline flow diverters.
- Vanguard Study: Pipeline Vantage 6-Month Results
- The technical success rate was 98%. The mean clinical follow-up time was 5.5 months. In
- patients presenting with unruptured aneurysms there were no deaths, 3 (6.4%) major
- complications and 7 (13%) minor complications.
- Posterior Circulation: Pipeline Vantage
- The efficacy and safety of the Pipeline Vantage in treating posterior circulation saccular
- aneurysms are not well investigated. At the latest imaging follow-up available (median 14.3
- months), complete aneurysm occlusion (Class I, Raymond-Roy occlusion classification)
- was achieved in 50% of cases, residual neck (Class II) in 41.7%, and residual aneurysm
- (Class III) in 8.3%. These posterior circulation occlusion rates are meaningfully lower than
- anterior circulation benchmarks, reinforcing the warning to reserve posterior/giant cases for
- high-volume operators.
- Key Landmark Trials: Pipeline Evidence Pyramid
- Trial
- Year
- n
- Key Finding
- PITA
- 2008
- Proof of concept;
- 93% occlusion at 6
- months
- PUFS
- 2013
- 73.6% complete
- occlusion;
- durability of
- large/giant ICA
- treatment
- IntrePED
- 2015
- Real-world safety;
- 8.4% neurologic
- morbidity/mortality
- SHIELD (surface)
- 2018
- Bench/clinical
- PC coating
- reduces
- thrombogenicity
- ADVANCE
- (Vantage)
- Ongoing
- RCT
- Fourth-generation
- RCT; NMPA/FDA
- registration
- Vanguard
- 2024
- 47+
- 98% technical
- success; 6-month
- results published
Deployment
Deployment Sequence
Position 0.027" microcatheter distal to neck; unsheath distal end and anchor Deploy with push-and-torque (“load and pull”) ensuring wall apposition across the neck Massage with wire or balloon if mal-apposed; confirm with VasoCT or cone-beam CT For large sacs: jail a coiling microcatheter and add loose coils before final detachment ──────────────────────────────────────────────────
Want the other 87 devices?
Selection decision-trees, the regulatory map, and illustrative cases are included with a code.
Enter access code